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Unresectable localized neuroblastoma: improved
survival after primary chemotherapy including
carboplatin-etoposide
H Rubie, J Michon, D Plantaz, MC Peyroulet, C Coze, D Frappaz, P Chastagner, MC Baranzelli, F Mechinaud,
P Boutard, P Lutz, Y Perel, G Leverger, L de Lumley, F Millot, JL Stephan, G Margueritte and 0 Hartmann for the
Neuroblastoma Study Group of the Societe Fran9aise d'Oncologie Pediatrique (SFOP)
Summary Neuroblastomas (NBs) were assessed according to INSS recommendations including MIBG scan and extensive bone marrow
staging to eliminate metastatic spread. Patients with unresectable tumour received primary chemotherapy including two courses of
carboplatin-etoposide (CE) and two of vincristine-cyclophosphamide-doxorubicin (CAdO). Post-operative treatment was to be given only in
children over 1 year of age at diagnosis who had residual disease orlymph node (LN) involvement. Between 1990 and 1994, 130 consecutive
children were registered. In comparison with resectable primaries, these tumours were more commonly abdominal, larger and associated
with N-myc amplification (NMA). Complete, very good and partial response (CR, VGPR, PR) to CE were, respectively, 1%, 7% and 44%,
overall response rate (RR) to two courses of CE and two courses of CAdO was 71%, and the tumour could be removed in all but four of the
children. The toxicity was manageable. The 5-year overall survival (OS) and event-free survival (EFS) were, respectively, 88% and 78% with
a median follow-up of 38 months. In multivariate analysis, only NMA and LN involvement adversely influenced the outcome, particularly NMA.
Children with unresectable NBs and no NMA fared as well as children with resectable ones as OS were, respectively, 95% and 99% and EFS
89% and 91%. Our data show encouraging results in localized but unresectable NBs as 90% of children may be considered as definitely
cured, especially those without NMA.
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Neuroblastoma (NB) is the most common solid tumour of early
childhood (Bernstein et al, 1992). Approximately 50% of patients
present with localized tumours (Hartmann et al, 1983; Rosen et al,
1984a) and radical surgical excision is generally considered as the
main requirement for cure (Evans et al, 1976; Le Toumeau et al,
1985). Primary surgery can be performed in about half of these
children and reported survival rates are high (De Bernardi et al,
1995). However, unresectable tumours usually have a poorer
outcome, unless secondary radical excision can be performed
(Rosen et al, 1984b; Haase et al, 1989; Tsuchida et al, 1992).
Consequently, the efficacy of primary chemotherapy to allow
subsequent resection is of outstanding importance (Garaventa et
al, 1993; West et al, 1993). We previously reported the efficacy of
the combination ofcarboplatin and etoposide (CE) in refractory or
relapsed NBs (Frappaz et al, 1992) and investigated its relevance
as a first line therapy in unresectable NBs.
In 1990, a national prospective study (NBL 90) was initiated,
registering all children with localized NBs diagnosed in the insti-
tutions of the French Society of Pediatric Oncology (SFOP). The
Primary aim was to assess the efficacy and the safety of such
chemotherapy as primary treatment in unresectable NBs,
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including dumbbell tumours. We report herein the results of this
treatment strategy.
PATIENTS AND METHODS
Patient population
Untreated children aged from 0 to 16 years were eligible. The
primary tumour was evaluated using computerized tomography
(CT)-scan or magnetic resonance imaging (MRI) as well as
metaiodobenzylguanidine (MIBG) scintigraphy. Work-up to elim-
inate metastatic spread included the skeletal study by MIBG (or a
99mTc scan in the absence of MIBG uptake at the primary site),
radiograph in infants and extensive bone marrow staging (at least
two aspirations and two trephine biopsies). Urinary catechol-
amines (VMA, HVA and dopamine), serum neuron-specific
enolase (NSE), ferritin and lactate dehydrogenase (LDH) levels
were measured. The diagnosis of NB was always confirmed by
cytological or histological documentation. The primary tumour
was staged according to TNM (Beahrs, 1983) and INSS (Brodeur
et al, 1993). However, those unresectable NBs did not overlap
completely with INSS stage 3 tumours. Indeed, according to our
definition of resectability using radiological data, those tumours
were not operated first and some of them were INSS stage 2 (i.e.
lateral tumours encasing regional organs or vessels and dumbbell
tumours). Analysis of the N-myc oncogene (Seeger et al, 1985)
This work has been in part reported at the XXIIIth meeting ofthe SIOP (Rhodes, 1-4
October 1991) and the ASCO meeting (Orlando, 16-18 May 1993).
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Figure 1 Chemotherapy regimen *First period (March 1990-April 1991): Carboplatin (160 mg/m2/d)-Etoposide (100 mg/m2/d) x 5 days. Second period (April
1991-December 1994): Carboplatin (200 mg/m2/d)-Etoposide (150 mg/m2/d) x 3 days. **Each course was to be administered every 21 days or as soon as
haematological criteria were met (WBC > 109/l, PMN .0.5 x 109/l, Platelets > 100 x 109/l). ***Vincristine: maximum dose of 2 mg. N.B. Some newborn received
only Vincristine (0.05 mg/kg D1) and Cyclophosphamide (5mg/kg D1-D5)
was recommended for all tumours and amplification (NMA) was
defined as the presence often copies or more per haploid genome.
Surgery
Participating institutions were provided with guidelines for surgical
procedures. Resectability was defined according to imaging data.
Procedures that would have resulted in the removal ofmajor organs
were not recommended unless initial chemotherapy had been
administered before any attempt of excision. Tumours defined as
unresectable were lesions that crossed and infiltrated the mid-line
structures, usually encasing large vessels, and tumours that because
of size, structure or location were difficult to resect without a high
risk of rupture or major surgical complications. All dumbbell
tumours were deemed unresectable and were urgently assigned to
chemotherapy. Post-operative imaging (CT scan and/or MRI) was
required in all patients 1 month after resection. Post-surgical
staging was defined on the basis of surgical, pathological reports
and post-operative imaging data.
Chemotherapy
Primary chemotherapy consisted of two courses of CE given as
previously described (Frappaz et al, 1992), followed by two courses
of vincristine, cyclophosphamide and doxorubicin - CAdO (Figure
1). AfterApril 1991, the dose intensity ofCE was decreasedbecause
of unacceptable haematological toxicity. Drug doses were always
reduced by 30-50% in infants or in children weighing less than
10 kg. After surgery, chemotherapy was indicated in children over
1 year at diagnosis in cases of residual disease and/or lymph node
(LN) involvement, or in infants with NMA. Such patients were to
receive alternated CE with CAdO for one course each. In patients
over 1 year at diagnosis with a persistent macroscopic residue after
chemotherapy, a second-look surgical procedure was recommended
after post-operative chemotherapy. On the whole, children received
a maximum ofthree courses ofeach combination.
Radiotherapy
In case of a persistent macroscopic residue at the end of the treat-
ment, irradiation ofthe tumour bed was scheduled only in children
over 1 year at diagnosis. Doses that ranged from 25 to 35 Gy
according to age were delivered in daily fractions of 1.5 to 1.8 Gy
each. As of November 1992, locoregional irradiation was recom-
mended for children whose tumour had NMA because of a high
Table 1 Patient characteristics with localized and unresectable
neuroblastoma
Unresectable Resectable
Cases number (%) number (%) P
130 (41) 186 (90)
Sex male 68 (52) 99 (53) NS
Age (months)
Median (range) 14 (0-192)
< 12 months 52 (40) 100 (54) 0.01
Site of primary tumour
Abdomen, lateral 55 (42) 97 (52)
Abdomen, median 30 (23) 9 (5) 10-
Mediastinal 32 (25) 55 (30)
Pelvic 10 (8) 10 (5)
Cervical 3 (2) 15 (8)
Dumbbell 34 (26) 8 (4)
TNM Stage
Ti 17 (13) 100 (54) 10-7
T2 69 (53) 73 (39) 10-2
T3 44 (34) 11 (6) 10-7
T5 0 2(1)
Initial histology
Neuroblastoma 57/77 (74) 118/182 (55) NS
MIBG scintigraphy
Positive 118/125 (94) 127/161 (79) 2.10-4
Elevated urinary 111/120 (92) 94/138 (68) 10-
catecholamine excretion
Abnormal NSE 95/107 (89) 85/117 (73) 2.10-3
Abnormal ferritin 15/87 (17) 11/98 (11) NS
Abnormal LDH 58/75 (77) 56/90 (62) 0.04
N-mycanalysis
2 10 copies 17/86 (20) 5/139 (4) 5.10-5
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Figure 2 Response to chemotherapy induction. CE, carboplatin-etoposide;
CR, complete response; VGPR, very good partial response; PR, partial
response; NR, no response; PD, progressive disease; NE, not evaluable.
*Toxic death (n=1), after cyclophosphamide-vincristine
incidence of local relapses, regardless of the age or the quality of
surgical excision.
Evaluation of response to therapy
Response to therapy was assessed according to INRC criteria
(Brodeur et al, 1993). The value of tumour response, based on a
reduction in volume that was considered more significant than that
of urinary catecholamine excretion, was evaluated during induc-
tion therapy (every two courses) before and 1 month after surgery,
at the end ofthe treatment, and then at least every 3 months.
Statistical analysis
To prevent selection bias, all consecutive patients with newly diag-
nosed localized NB in the participating centres were included in
the analysis, whatever the treatment actually administered. The
probabilities ofsurvival were calculated from the time ofdiagnosis
to death or last follow-up according to the Kaplan-Meier
product-limit method (Fleiss, 1981). In the EFS analysis, disease
progression or relapse and death, whatever the reasons, were
considered as events. Comparisons between proportions were
performed with the X2-test corrected for heterogeneity or Fisher's
exact test (Peto et al, 1977). Multivariate assessment ofEFS times
was performed by Cox's proportional hazards model and differ-
ences between curves were tested for statistical difference by the
log-rank test (Cox, 1977). Potential prognostic factors were
included in the multivariate model, provided the number ofevalu-
able patients was sufficient. All tests are two-tailed.
RESULTS
From March 1990 to December 1994, a total of 337 consecutive
children with localized NB were registered in the study. Of those,
21 were excluded because the tumour was a total mature
ganglioneuroma. Among the 316 remaining children, 186 under-
went primary surgical excision. Therefore, the present analysis
concerns 130 patients and reports the outcome of patients as of
June, 1997, 30 months after the last patient's inclusion.
Patient characteristics (Table 1)
The median age was 14 months and 12 children were newborn.
Compared with resectable NBs, unresectable tumours were more
frequently observed in older children, abdominal site (65%) and
Table 2 Post-surgical staging according to initial treatment
Initial surgery Initial chemotherapy
(n = 186) (n = 130)
Response No response Not assessed
TNM post-surgical staging (n=86)* (n=41)** (n=3)***
pSI: complete resection, 72 11 1
negative nodes (n = 84)
pSIl: complete resection, 24 3 0
positive nodes (n = 27)
pSIlla: microscopic residue 63 39 20 2
(n= 124)
pSIlIb: Macroscopic residue 15 23 13
< 10% (n= 51)
pSIlc: macroscopic residue > 10%
or biopsy (n= 25) 12 7 6
*No surgery, n = 3 (complete remission after chemotherapy n = 1; progressive disease n = 2). **No surgery, n = 1 (progressive disease n = 1). ***Not assessed,
n = 3 (no imaging n = 2; toxic death before surgery n = 1).
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larger. Large tumours (T3, diameter > 10 cm) were more common
in the abdomen (37 out of 85, 43%) than in the chest (6 out of 32,
19%) (P = 0.02). Positive MIBG uptake of the primary and
elevated biological markers were more frequent in those tumours
as well as NMA. Dumbbell tumours were found in 34 children, of
whom 27 had a neurological deficit and are described more
precisely elsewhere (Plantaz et al, 1996).
Primary chemotherapy
Response (Figure 2)
Of the 130 children assigned to receive primary chemotherapy,
113 had CE as first courses, according to the protocol. Four of
them were not evaluable: two patients had major complications
after the first course (intratumoral haemorrhage, n = I and dissem-
inated candida infection, n = 1), and then underwent complete
surgical excision; two additional patients had no imaging evalua-
tion. Ofthe 109 children evaluable after the two courses ofCE, 57
(52%) had a response >50% (CR n = 1; VGPR n = 8; PR n = 48),
50 patients did not respond and two progressed while on therapy.
Among the 17 children receiving CAdO as first courses, a
newborn presenting with a large thoracic and dumbbell tumour
died from a massive pulmonary embolism a few days after initia-
tion of chemotherapy, seven had PR and nine failed to respond.
After these two first courses, 17 out of 129 children underwent
surgical resection, either because of chemotherapy-induced
complications (n = 2) or because of the physician's decision
(n = 15). Thus, 112 children received two consecutive courses of
chemotherapy according to the protocol; among the 108 evaluable
for response after each series of two courses, 21 of the 51 (41%)
who did not respond to the first courses responded to the new
combination. Consequently, the overall response rate (RR) was
71%, regardless of the type of chemotherapy. Dumbbell tumours
responded as well as other primaries (Plantaz et al, 1996). Finally,
all but five ofthe children underwent surgery: one died early, three
had progressive disease and died ofthe disease and one was in CR
according to imaging data. As shown in Table 2, of the 125 chil-
dren evaluable for surgery, 76 (61Y%) had complete removal of
tumour, compared with 159 out of 186 (85%) resectable primaries
(P = 8.10-6). Among the 49 patients with macroscopic residual
disease, 14 underwent a second-look procedure (after two addi-
tional courses of chemotherapy in five) leading to a secondary
complete resection in eight. Finally, given that the ultimate goal
was achievement of CR, primary chemotherapy allowed radical
Table 3 Toxicity of carboplatin - etoposide.
First period* Second period* Psignificance
Number of evaluable courses 111 274
Leucopenia (WBC < 109/l)
n (%) 26 (23) 34 (12) 7.10-3
Median duration - days (range) 4 (1-19) 5 (1-3) NS
Neutropenia (PMN < 0.5109/l)
nf(%) 76 (67) 123 (45) 104
Median duration - days (range) 7 (1-15) 7 (1-17) NS
Thrombocytopenia (Plts < 50109/l)
n (%) 57 (51) 84 (31) 10-A
Median duration - days (range) 2 (1-14) 3 (1-13) NS
Transfusions
RBC
n (%) 52 (47) 75 (27) 2.10A
Median number (range) 1 (1-3) 1 (1-3) NS
Platelets
n (%) 42 (38) 66 (24) 2.10-3
Median number (range) 1 (1-6) 1 (1-5) NS
Fever> 380C
n (%) 38(34) 63(23) 2.10-2
Median duration - days (range) 4 (1-30) 2 (1-10) 4.10-3
Documented infection
n (%) 12 (11) 32 (12) NS
Intravenous antibiotics
n (%) 17 (15) 36 (13) NS
Median duration - days (range) 12 (2-40) 8 (1-28) NS
Alteration of creatinine clairance
(drop > 30% of initial value)
n (%) 4/33 (12) 3/48 (6) NS
Alteration of audiometry
nf(%) 0/28 0/23
Miscellaneous 0 2 (1)**
*First period from March 1990 to April 1991. Second period from April 1991 to December 1994 (schedule and doses are detailed Figure 1).
**Anaphylaxis after etoposide.
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Table 4 Prognostic factors
Eventpatient Univariate analysis
No (EFS) P-value (log rank) Hazard ratio
Sex
Male
Female
Age
0-12 months
> 12 months
- Site of primary tumour
..Abdominal
Non abdominal
Abdominal median
Right
- Left
15/68 (77)
13/62 (78)
5/52 (90)
23/78 (69)
24/85 (72)
4/45 (91)
9/30 (68)
10/26 (49)
5/29 (81)
NS
7.10-3 2.75 (1.1-3.8)
2.10-2 3.6 (1.2-10.4)
2.10-2
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Figure 3: Event-free survival (EFS) of children with unresectable and
resectable neuroblastoma (NB). - EFS children with resectable NB (n=186)
= 88 + 3%.- - - EFS children with unresectable NB (n=130) = 78 ± 6%
excision to be performed in 67% of patients with unresectable
tumour at diagnosis.
Toxicity
The main data are listed in Table 3, including primary and/or post-
operative chemotherapy. The toxicity of the CE regimen was
mainly haematological and manageable. During the first period of
the study, more than half of the patients experienced WHO grade 4
cytopenia. Transfusions were necessary in nearly half of the
patients. Four major chemotherapy-related complications were
observed: one child had a life-threatening infection after the first
course, then underwent surgery and received four subsequent
courses without any complication; another one had an intracerebral
haemorrhage associated with CE-related thrombocytopenia and is
alive without sequelae; the last two patients developed virus C
hepatitis after transfusion. Therefore, the total doses of this combi-
nation were subsequently reduced in April 1991. Among the 274
courses given thereafter, the incidence ofneutropenia, fever, throm-
bocytopenia and transfusions was significantly lowered and no
major complication was observed. In addition, the RR was not
compromised (respectively 58% and 50% for the first and the
second period). Regarding renal toxicity, the reduction in creatinine
clearance was transient. The toxicity ofCAdO was haematological.
Briefly, among the 215 evaluable courses, red blood cell and
platelet transfusions were given in respectively 49% and 11% of
patients, WHO grade 4 neutropenia was observed in 70% of
patients and documented infection in 27%, and intravenous anti-
biotics were administered in 45% ofchildren. All the complications
were easily manageable. However, granulocyte colony-stimulating
factor has been administered after 30% ofthe courses, and that may
have lowered neutropenia incidence and its duration.
Post-operative treatment
Chemotherapy
Among the 113 children with either a complete resection and posi-
tive LN or residual disease after surgery (Table 2), 65 were over 1
year at diagnosis. Fifty-seven received two post-operative courses
Size of primary tumour
Tl 2/17 (88)
T2 6/69 (91)
T3 20/44 (54)
Histological lymph node invasion
No 5/72 (92)
Yes 17/47 (62)
MIBG uptake
Positive
Negative
Initial cytology or histology
Neuroblastoma
Ganglioneuroblastoma
Urinary catecholamines
VMA/HVA > 1
VMA/HVA < 1
Dopamine
<2000
2000-3000
>3000
NSE
Normal
Abnormal > 2 N
Ferritin
Normal
Abnormal > 2 N
23/118 (80)
5/7 (29)
14/57 (75)
3/20 (82)
6/53 (91)
22/74 (68)
9/64 (86)
3/11 (73)
15/45 (64)
0/12 (100)
20/75 (74)
15/73 (80)
4/11 (70)
LDH
Normal 1/17 (94)
Abnormal > 2 N 7/15 (53)
N-myc amplification
< 10 copies 7/69 (89)
> 10 copies 10/17 (41)
Response to initial chemotherapy
CRNGPR/PR 21/83 (75)
NR/PD 6/45 (84)
Results of surgery
CR
VGPR + PR
Final result of therapy
CR
No CR
Protocol compliance
Good
Violation
12/76 (85)
12/49 (75)
12/93 (87)
13/36 (65)
24/106 (78)
4/21 (80)
10-5 5.6 (2.5-12.7)
3.10-5 6.17 (2.3-16.6)
7.104 4.65 (1 .7-12.2)
NS
5.10-3 2.68 (2.1-3.4)
NS
10-2 2.15 (1.1-6.6)
NS
NS
10-2 8 (1.6-39.6)
7.10-7 7.09 (2.8-18.1)
NS
NS
10-4 3.8 (1.8-8)
NS
Multivariate analysis*
P-value Hazard ratio
N-mycamplification 2.10 4 7.8 (2.6-23.2)
Histological lymph node 6.10-3 6.1 (1.7-22.3)
involvement
*Analysis performed in patients with age, size and site of the primary, MIBG uptake,
histological lymph node involvement and N-mycamplification all evaluable (n = 75).
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of chemotherapy according to the protocol, and in eight cases no
further therapy was given (poor general condition, n = 2 or
protocol violations, n = 6).
Radiotherapy
After the amendment, radiotherapy was given in four children in
CR (two infants), because NMA was documented. Among the 36
children with a persistent macroscopic residue at the end of treat-
ment, 15 were under 1 year of age and irradiation was omitted in
all but two (protocol violations). Conversely, of 21 older patients,
eight were not irradiated according to the physician's judgement.
Irradiation was delivered in 13, with final tumour doses ranging
from 20 to 45 Gy (mean tumour dose 32.32 ± 6.28 Gy) and fields
including vertebrae 1-11 (mean 4,6). No immediate toxicity was
reported. Owing to the protocol, radiation therapy was finally
avoided in 26 out of 49 patients (53%) who had a post-operative
macroscopic residue.
Outcome
Among the 130 children, the disease status at the end of treatment
was CR in 93 (72%), VGPR in 27, PR in one, NR in one and PD in
seven. With the present follow-up (FU), an event occurred in 28
(21%) children. Two patients died of treatment-related toxicity,
either after chemotherapy (n = 1) or after subsequent surgery (n =
1) and one of an unexplained cause (18 months after diagnosis).
Seven patients developed PD, of whom one is alive and disease-
free after salvage therapy including high-dose chemotherapy
(HDC) and bone marrow transplantation (BMT). Eighteen chil-
dren experienced a relapse that was either local (n = 13),
metastatic (n = 3) or combined (n = 2), at a median time of 7
months after diagnosis (range 2-27 months).
As of June 1997, 113 out of 130 children are alive, with a
median FU of 38 months (range 30-84 months). Eight patients
developed severe sequelae (neurological and/or orthopaedic), all
arising in dumbbell tumours exhibiting symptoms (Plantaz et al,
1996). One child developed major acute renal failure after
secondary surgery, leading to kidney transplantation, and is still
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Figure 4 Event-free survival (EFS) of children with no N-m
according to primary resectability. - Resectable NBs (n=13
91 ± 4%. - - - Unresectable NBs (rn=69). EFS=89 ± 8%. Log
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alive in remission. One child presented with Ewing's sarcoma 3
years after initial diagnosis and is still in remission 30 months
later.
Survival and prognostic factors
As shown in Figure 3, the projected overall survival (OS) and
event-free survival (EFS) rates at 5 years were respectively
88% ± 6% and 78% ± 6% with a median follow-up of 38 months
(range 30-84 months). Table 4 shows the univariate and multi-
variate analysis of all the usual prognostic factors. Despite infants'
treatment being reduced, their outcome was better than older chil-
dren. In the univariate analysis, a large primary influenced adver-
sively the outcome, as well as abdominal site, histologically proven
LN involvement, low VMAIHVA ratio, elevated LDH and NMA.
When the established prognostic factors were combined with NMA
in the Cox regression model, NMA was the most powerful indi-
cator of poor outcome. EFS was far better in the 69 children with
less than ten copies compared with the 17 with NMA (89% vs
41%) (log rank = 7.10-7). Subsequent relapse was observed in 10
out of 17 children with NMA, either local (n = 5), metastatic (n = 3)
or combined (n = 2), from 3 to 17 months after diagnosis. All of
them ultimately died of disease despite salvage therapy including
HDC followed by BMT (n = 4). As shown in Figure 4, children
with unresectable NB and no NMA fared as well as children with
resectable tumour, as OS were respectively 95% ± 5% and
99% ± 5%, and EFS were 89% ± 8% and 91% ± 4% (log rank =
0.7). The only other significant prognostic factor was histological
LN invasion. However, in children without NMA, the outcome of
those with positive (n = 25) and negative LN (n = 42) was compa-
rable (EFS respectively 82% ± 16% and 95% ± 7%, P = 0.12).
DISCUSSION
Unresectable NB usually carries a poor prognosis as achieving
EFS greater than 50% has proven difficult, despite introducing
chemotherapy in the early 1980s (Evans et al, 1984; Rosen et al,
1984b). Encouraging results have recently been reported using
more intensive regimens with improved EFS to 60-70% (Nitschke
et al, 1991; Garaventa et al, 1993; West et al, 1993; Castel et al,
1995). However, such efficacy should be balanced with the risk of
treatment-related sequelae as most of these regimens included
high cumulative doses of alkylating agents, doxorubicin and cis
platinum and sometimes radiotherapy (Castleberry et al, 1991).
This led us to design a prospective, multicentric study using
modem tools for assessment and evaluating new and presumably
less toxic treatment schedules in localized but unresectable NBs.
Biased selection was avoided by registering all consecutive
cases of localized NBs. Although our definition of unresectable
tumours relied on imaging and not operative findings, patient
characteristics were similar to those of other published series
(Garaventa et al, 1993; West et al, 1993; Castel et al, 1995).
The therapeutic strategy chosen provided good results as nearly
90% of patients are long-term survivors and probably cured. This
result should be emphasized as it differs from previous reports.
Two reasons may account for our encouraging results. First, local-
ized tumours were rigourously selected according to INSS recom-
mendations throughout work-up that included initial MIBG
scintigraphy and extensive bone marrow staging to eliminate
metastatic dissemination. Such extensive staging has not been
performed in all children in the most recent studies (Garaventa et
BritishJournal ofCancer(1998) 77(12), 2310-2317
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al, 1993; West et al, 1993; Castel et al, 1995), which may have
included some cases with undetected metastatic disease. As a
matter offact, many ofthe patients described in these studies expe-
rienced disseminated recurrences, as opposed to 4% of metastatic
relapses (28% of the relapses) in our series. Second, most authors
agree that the degree of surgical excision in localized NB will
influence outcome (Evans et al, 1976; Le Tourneau et al, 1985;
Haase et al, 1989; Garaventa et al, 1993). Consequently, primary
chemotherapy permitting radical surgery, and perhaps also post-
operative treatment, may exert a major impact on outcome. Similar
findings from other groups support the idea that an increase in
treatment intensity improves EFS in children with extensive local
and regional NB (Castleberry et al, 1991; Garaventa et al, 1993;
West et al, 1993; Castel et al, 1995).
The efficacy of CE combination has been previously reported
(Frappaz et al. 1992). The present study confirms its efficacy,
when combined with CAdO as the overall tumour response rate
was over 70%, and 97% of the patients could undergo surgical
resection. Although the incidence of persistent macroscopic
residual disease was still higher than in resectable NBs, the EFS
rate ofthose children was still good (75% vs 85%). Moreover, this
chemotherapy combination appears appropriate in dumbbell
tumours as neurological recovery was observed in 90% of cases
without laminectomy (Plantaz et al, 1996). Amazingly, response to
chemotherapy was not predictive of subsequent outcome. One
may suggest that NBs considered as NRs included tumours with
10-49% shrinkage, which could be sufficient for radical excision;
the similar incidence ofmacroscopic residue in responding (30 out
of 83 = 36%) and non-responding patients (19 out of 40 = 47%)
might support this hypothesis. Furthermore, NRs have probably
occurred in more mature tumours, which might have a lower risk
of subsequent relapse. The toxicity of the chemotherapy regimen
used was acceptable. The only toxicity-related death occurred after
small doses of cyclophosphamide-vincristine, and the fatal
pulmonary embolism could have been caused by the large thoracic
tumour as well. Although the chemotherapy regimen was short
and total cumulative doses of drugs were low (maximum doses of
carboplatin = 1.8-2.4 g m-2 according to the period of study,
cyclophosphamide = 4.5 g m-2, doxorubicin = 180 mg m-2), there
is still concern about the possible late side-effects and the long-
term evaluation of audiometry and renal function is needed to
confirm the optimal cost-benefit ratio.
The significance of prognostic factors in such a population is
still controversial. Age is one of the most powerful (Evans et al,
1976; Hartmann et al, 1983; Garaventa et al, 1993). In our study,
despite the de-escalation of post-operative treatment in infants,
EFS was better than in older children. Given these results, less
intensive chemotherapy will be prospectively evaluated in infants
in the next trial. We confirm that abdominal primaries had a signif-
icantly worse outcome than non-abdominal sites. The adverse
outcome of patients with a right-sided abdominal tumour may be
due to the more difficult surgical resection in that site. Children
with large tumours (T3) fared significantly worse than those with
small ones and it should be pointed out that 84% of those were
abdominal. Actually, the most relevant finding in this study was
the extremely powerful significance of NMA in this population.
Correlations between NMA and the usual adverse prognostic
factors have been firmly established (Seeger et al, 1985; Brodeur
et al, 1992), and we have recently confirmed its negative influence
on outcome in localized NBs (Rubie et al, 1997). Among the 86
tumours analysed before any adjuvant treatment, NMA was found
in 20% of the tumours and correlated with well-known adverse
prognostic factors such as age, site and the size of the primary and
elevated biological markers. Furthermore, once they relapse, these
children cannot be salvaged by any kind of second-line treatment
as all died a few months later. Our finding differs from the POG's
data (Cohn et al, 1995), but their study did not include stage C
tumours. Indeed, this selection may have reduced the incidence of
amplified tumours as in our series of localized NBs, 17 out of 22
children with NMA had an unresectable primary. In the multi-
variate analysis, LN invasion ranked second. The poor prognostic
value of LN involvement has been pointed out by some authors
(Ninane et al, 1982; Castleberry et al, 1991; De Bemardi et al,
1995) but not necessarily confirmed by others (Rosen et al, 1984c;
Matthay et al, 1989). In the present series, LN invasion had an
adverse effect on outcome, but this predictive value was no more
significant in patients without NMA, underlining the significance
of such genetic alteration in patients with regional disease.
In conclusion, our data show excellent results in localized but
unresectable NBs. The combination of CE followed by CAdO
appears to be the appropriate primary treatment in children with
such tumours, including dumbbell lesions. N-myc amplification,
arising in 20% of these tumours, is the most powerful prognostic
factor, and an innovative approach is warranted in this subset of
patients. With this treatment strategy, patients with unresectable
NB and without NMA fared as well as those with resectable
primary and do not need stage 4 strategies.
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